Cerus Corporation CERS
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +10.68%
- 1 year
- +62.86%
- Open
- 2.41
- Prev close
- 2.44
- Mkt cap
- 459.48M
- Vol
- 1.50M
- Avg vol
- 2.02M
- EPS
- -0.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.26
- High
- 2.41
- Forward P/E
- -22.57
- Beta
- 1.20
- Short ratio
- 4.10
- Inst. own
- 79.22%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.74
- 200-d avg
- 1.88
- 1y target
- 3.90
YTD chart
Signals (37)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| RSI: Oversold | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| RSI: Overbought | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 25, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 11, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 27, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 13, 2026 | 9 months ago |
| RSI: Overbought | Jan 13, 2026 | 9 months ago |
Key statistics
- Market cap
- 293.43M
- Enterprise value
- 316.56M
- Trailing P/E
- 0.00
- Forward P/E
- -22.57
- PEG ratio
- 0.00
- Price / sales
- 1.67
- Price / book
- 5.49
- EPS (TTM)
- -0.11
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -11.19%
- Revenue (TTM)
- 176.23M
- Revenue growth
- 15.70%
- Free cash flow
- -9.08M
- Total cash
- 75.56M
- Total debt
- 97.90M
- Return on equity
- -38.31%
- Shares outstanding
- 185.72M
- Short % of float
- 4.76%
- 50-day average
- 1.74
- 200-day average
- 1.88
Analyst view
Consensus: none
- Target (low)
- 2.50
- Target (mean)
- 3.90
- Target (high)
- 5.00
- Strong buy0
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.0125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.03 | -0.02 | +0.01 | +33.33% |
| Aug 1, 2024 | Jun 1, 2024 | -0.04 | -0.03 | +0.01 | +25.00% |
| May 2, 2024 | Mar 1, 2024 | -0.04 | -0.05 | -0.01 | -25.00% |
| Mar 5, 2024 | Dec 1, 2023 | -0.01 | -0.01 | 0.00 | 0.00% |
| Nov 2, 2023 | Sep 1, 2023 | -0.05 | -0.03 | +0.02 | +40.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.05 | -0.07 | -0.02 | -40.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2024 | Stifel | main | Buy | Buy |
| May 3, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Apr 12, 2024 | Craig-Hallum | init | — | Buy |
| Mar 7, 2024 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Mar 6, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jan 20, 2023 | BTIG | down | Buy | Neutral |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cerus.com
News
- Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
- RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis
- Cerus: This Blood-Safety Underdog Should Be Earning More Respect
- Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS
- Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
- Cerus Q2 Earnings Call Highlights
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate
Your note
Sign in to keep a note on CERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENJAMIN RICHARD J. | Officer | Sale | Aug 1, 2024 | 438,007 |
| BJERKHOLT ERIC H | Director | Sale | Dec 11, 2024 | 162,133 |
| GREEN KEVIN DENNIS | Chief Financial Officer | Sale | Sep 3, 2024 | 536,093 |
| GREGORY DEAN A. | Director | Stock Award(Grant) | Jun 30, 2024 | 60,000 |
| JENSEN CHRYSTAL MENARD | Officer | Sale | Dec 15, 2024 | 457,578 |
| MOORE TIMOTHY L. | Director | Stock Award(Grant) | Jun 4, 2024 | 145,073 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 10.49% | 19,477,339 | 30.77M | Sep 29, 2024 |
| ARK Investment Management, LLC | 9.81% | 18,225,031 | 28.80M | Sep 29, 2024 |
| Blackrock Inc. | 7.90% | 14,669,054 | 23.18M | Sep 29, 2024 |
| Vanguard Group Inc | 5.84% | 10,848,098 | 17.14M | Sep 29, 2024 |
| Primecap Management Company | 4.60% | 8,544,000 | 13.50M | Sep 29, 2024 |
| Wasatch Advisors LP | 3.94% | 7,325,834 | 11.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 6.96% | 12,931,823 | 20.43M | Oct 30, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 4.60% | 8,544,000 | 13.50M | Sep 29, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 4.42% | 8,208,021 | 12.97M | Oct 30, 2024 |
| Wasatch Ultra Growth Fund | 3.69% | 6,849,908 | 10.82M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.98% | 5,535,900 | 8.75M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.50% | 4,644,437 | 7.34M | Oct 30, 2024 |